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Gene Polymorphisms That 




Down syndrome caused by presence of extra chromosome 21 originates from 
nondisjunction during parental gametogenesis. For overwhelming cases, the error 
occurs in oocyte and all the nondisjunction events are not stochastic. With increas-
ing number of research efforts, it has come to know that maternal genetic archi-
tecture may be considered as risk factors for chromosomal errors. Polymorphisms 
of the genes involved in chromosome segregation, recombination and folic acid 
metabolisms have been investigated for their association with Down syndrome 
child birth. But the results are conflicting owing to ethnic and sociocultural dif-
ferences. Here, we have discussed and summarized the outcome of the studies 
conducted on different population sample from different parts of world and tried to 
figure out the common polymorphisms, which could be used as makers for precon-
ceptional screening of Down syndrome child birth risk among the women.
Keywords: down syndrome, maternal genotype, polymorphism, meiotic 
nondisjunction
1. Introduction
Down syndrome (DS), the most common form of live born intellectual dis-
ability in human is caused by trisomy condition of chromosome 21 (Ch21). The 
trisomy 21 condition arise from nonseparation or nondisjunction (NDJ) of Ch21 in 
germinal cells that leads to production of disomic gamete which upon fertilization 
with gamete with correct chromosome count from opposite sex produces trisomic 
zygote. For overwhelming majority of cases, the error arises in oocyte and this 
may be due to protracted phase of oocyte development. The lengthy process of 
oocyte maturation that includes two halts, one at meiotic I diplotene and another 
before the entry in second meiotic division, provides opportunity to environmental 
insults to accumulate in ovarian microenvironment that may perturb the process of 
chromosome segregation.
The first identified risk factor for Down syndrome birth is advanced maternal 
age of conception. It was identified that [1], women of age 32 years and above 
have higher risk of having Down syndrome baby. Subsequently, with the help of 
polymorphic variants of short tandem repeat (STR) makers on Ch21 scientists 
have characterized that recombination error may be the molecular risk factors for 
Ch21 NDJ. With elaborate analyses, considering both the maternal age and pattern 
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of recombination, the US researcher group [2] and Indian researcher group [3] 
have characterized the interaction between maternal age and erroneous pattern 
of recombination on non-disjoined chromosome. No chiasma formation or single 
telomeric chiasma have been proved as risk of Ch21NDJ at MI among the younger 
mothers (age < 29 years). On contrary, single centromeric chiasma has been identi-
fied as risk factors for MII errors among the older women (age > 34 years).
With subsequent analyses of maternal molecular age, it has been proved that 
mothers of Down syndrome baby have shorter average telomere length than do 
the mothers of same chronological age and have euploid healthy baby [4, 5]. The 
authors proposed that a group of women may suffer from advanced molecular and 
genetic aging and intuitively carry predisposition for NDJ. It is really difficult to 
interpret whether NDJ is the result of rapid shortening of telomere or telomere 
shortening and NDJ are linked by some common risk factors, instead it can be 
said pleiotrophic effects of some genes may relate maternal aging with risk of 
NDJ. Moreover, frequent occurrence Ch21 NDJ among younger women reinforces 
the intuitive idea of genetic predisposition for Ch21 NDJ where advancing maternal 
age is not an issue.
As far as published literatures are concerned studies for identifying the genetic 
predisposition for DS child birth among the women are not sufficient. Very few 
initiatives in this regard have been recorded. Of them the recombination regulator 
genes and folate metabolism regulator genes are major. So, this chapter presents 
recent updates on finding of the gene polymorphisms that exhibited significant 
association with Down syndrome birth.
2. PR/SET domain 9 (PRDM9)
The gene is located on chromosome 5 (5p14.2). The protein coded by this gene is 
a zinc finger protein with histone methyltransferase activity that catalyzes trimeth-
ylation of histone H3 lysine 4 (H3K4me3) during meiotic prophase. This protein 
contains multiple domains, including a Kruppel-associated box (KRAB) domain, an 
SSX repression domain (SSXRD), a PRD1-BF1 and RIZ homologous region, a sub-
class of SET (PR/SET) domain, and a tandem array of C2H2 zinc fingers. The zinc 
finger array recognizes a short sequence motif of histone, leading to local H3K4me3, 
and meiotic recombination hotspot activity.
Experimental deletion of the gene in mice leads to the production of gametes 
blocked at pachytene of meiosis I that show a reduced number of Dmc1 loci, a 
protein that indicates the sites of meiotic crossovers [6]. The major allele A of 
PRDM9 binds a 13 bp DNA motif enriched at recombination hot spot, namely, 
CNCCNTNNCCNC [7]. Further, allelic variation in the zinc finger motif of 
PRDM9 exhibited association with differential hotspot usage in human recom-
bination [8]. Carriers of PRDM9 minor alleles display reduced recombination at 
meiotic hotspots [8]. All these preceding observation led to the study [9] to inquire 
whether PRDM9 variants exhibit association with the recombination variation that 
underlies the NDJ events.
In this study [9] by US researcher group included 235 mothers having DS 
child and 85 controls having euploid baby. For characterizing the recombination 
profile along the 21q, the authors used genotyping with 1536 SNP loci on 21q by 
the Illumina Golden Gate Assay. The authors scored for 17% of cases of MI error 
without any recombination events carry homozygosity of minor alleles in contrast 
to only 2% of MI with single exchange category. The logistic regression analyses 
revealed women from MI without any exchange category are 2.45 times more likely 
to have risk of NDJ and Down syndrome birth than do the controls when carry at 
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least one minor allele in heterozygous condition. The authors found less affinity of 
minor allele of ZF motif of PRDM9 and they tried to justify this reduced binding 
of PRDM9 to the recombination hotspot may cause lack of recombination events 
on 21q and NDJ of Ch21. This notion needs further confirmation by other stud-
ies on different DS populations of ethnic variations for considering as acceptable 
hypothesis.
3. Apolipoprotein E (APOE)
This gene is located on chromosome 19 (19q13.32) and encodes a protein which 
is essential for normal catabolism of triglyceride-rich lipoprotein. It binds to spe-
cific receptor on hepatocytes and peripheral cell receptors. Mutations in this gene 
leads to familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP 
III), which is characterized by increased plasma cholesterol and triglycerides due 
of impaired clearance of chylomicron and VLDL remnants. The gene is expressed 
specifically in liver, kidney, adipose, adrenal, spleen and neuronal tissues along with 
some other organs at low level.
Initial study that addressed the maternal APOE genotypes as risk factors of DS 
birth [10] reported presence of APOE4 allele among women may predispose them 
for MII NDJ at the younger age, but not at older age. The authors observed in young 
mothers with a meiosis II error, epsilon4 frequency was 30.0%, which was signifi-
cantly higher than in older mothers with a meiosis II error (13.0%, P = 0.03).
But the study [11] conducted on Spanish population reported some opposite 
trend. The authors have observed an increased frequency of APOE4 allele among 
MI mother of age < 28 years as compared to MI mothers of age > 28 years. But this 
study did not confirm any association of maternal APOE4 genotype with MII error. 
The study on Colombian population [12] has revealed preferential occurrence of 
APOE4 allele in DS and their parents (11%) than among the controls (9%) though 
the difference was found insignificant statistically. More studies are needed to 
confirm the association between APOE4 allele in maternal genome and Ch21 NDJ.
4. Presenilin I (PSEN1)
This gene is located at the position 14q24.2 and known for its pleiotrophic 
effects. It has many isoforms that perform variety of functions. The polymorphisms 
of this gene were first reported for its association with Alzheimer disease. Later, it 
was tested for risk assessment in women having DS child.
As far as published literatures are concerned, only two studies have been 
conducted on PSEN 1 polymorphisms as a maternal risk factor for DS birth. The 
initial study was done on US population [13] where the authors find an associa-
tion between a polymorphism in intron 8 of maternal genotype with DS birth. 
This study included168 probands with free trisomy 21 and recorded an increased 
frequency of allele 1 in mothers with a meiosis II error (70.8%) than among the 
mothers of meiosis I error (52.7%, P < 0.01), with an excess of the 11 genotype 
in the meiosis II mothers. Moreover, the author tested polymorphic variants of 
APOE gene and found the frequency of allele 1 in mothers carrying APOE4 allele 
(68.0%) was higher than in mothers without APOE4 (52.2%, P < 0.01). The 
author hypothesizes that the PSEN-1 intronic polymorphism might be involved in 
chromosomal nondisjunction through an influence on the expression level of PS-1 
or due to linkage disequilibrium with biologically relevant polymorphisms in or 
outside the PS-1 gene.
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Similar study was conducted on a population samples from India [14]. In this 
study, 170 Down syndrome patients, grouped according to maternal meiotic stage 
of NDJ and maternal age at conception, and their parents were genotyped for 
PSEN-1 intron-8 and APOE polymorphisms. The estimated frequencies of the 
PSEN-1 T allele and TT genotype, in the presence of the APOE4 allele, were signifi-
cantly higher among young mothers (< 35 years) with meiosis II NDJ than in young 
control mothers (96.43 vs. 65.91% P = 0.0002 and 92.86 vs. 45.45% P < 0.0001, 
respectively) but not among mothers with meiosis I NDJ. The author hypothesized 
that the co-occurrence of the PSEN-1 T allele and the APOE 4 allele synergistically 
increases the risk of meiotic segregation error II among young.
5. Methylenetetrahydrofolate reductase (MTHFR)
This gene is located at 1p36.22 and the 12 exon long reading frame encodes 
an enzyme that catalyzes the reduction of 5,10-methylene tetra hydro folate to 
5-methyl tetra hydro folate, which is required for the remethylation of homocys-
tein to methionine. A common MTHFR 677C > T polymorphism (rs1801133) that 
results in Ala222Val amino acid substitution, is responsible for reduced enzyme 
activity. The homozygous TT genotype causes dimer destabilization under condi-
tions of reduced folate availability [15, 16]. It was reported initially [17] in the year 
1999, that increased plasma hcy level and an increased frequency of both MTHFR 
677CT and TT genotypes among the mothers of DS individuals are strongly linked 
and since then this polymorphism has been tested in more than 30 case-control 
studies across the globe and confirmed this association with very few exceptions. 
As far as published literatures are concerned five large meta-analyses have been 
done till date between the year 2013 and 2014 to address this issue [18–22], with 
the latest one that includes data from 34 case-control studies for a total of 3.098 
women having DS child and 4.852 control mothers [21]. The outcome of all these 
meta-analyses suggest that the overall risk as represented by odds ratio (OR), for 
the birth of a child with Trisomy21 to the women who are carriers of the 677 T 
allele ranges from 1.2 to 1.5 according to the various genetic models under inves-
tigation, i.e., allele contrast, dominant, recessive, co-dominant, etc. Subsequent 
data stratification into ethnic groups revealed that the risk is higher in Asians 
(OR = 1.5), and lower in Caucasians and/or other groups (OR usually ranging 
between 1.0 and 1.4) [19, 20, 22]. The meta-analyses performed by Wu et al. [19]; 
Yang et al. [20]; Rai et al. [21]; Victorino et al. [22] revealed that the frequency of 
the MTHFR 677 T allele is higher in Caucasian mother of DS child (ranging from 
35.6 to 41.5%), followed by Brazilians (ranging from 33.5 to 33.9%), and lower 
in Asian populations (ranging from 20.0 to 32.3%). When epidemiological data 
were stratified according to the geographic origin of the mothers and found that 
the higher risk in Asians (OR = 1.53; 95% CI = 1.29–1.82), followed by Americans 
(OR = 1.23; 95% CI = 1.07–1.39), and the association remain insignificant for 
Europeans (OR = 1.04; 95% CI = 0.93–1.16) [21]. When the data was stratified 
according to latitude, exhibited a significant association of the MTHFR 677C > T 
polymorphism with DS birth insub-tropical populations (both TT vs. CC and CT 
vs. CC carriers), followed by tropical regions (only CT vs. CC carriers), but no 
significant effect was evident in the population from northern temperate region 
of the globe. These observations suggest complex gene–environment interac-
tions, which might be a product of differences in allele frequencies among dif-
ferent populations in association with different nutritional status and exposure 
to environmental factors, such as solar radiation, that could interfere with folate 
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bioavailability [16, 23, 18, 22]. Interestingly, scientists have observed association of 
the MTHFR 677C > T polymorphism with both chromosome 13 and 21 malsegre-
gation events in lymphocytes from the mothers of DS child [23, 24].
Another common MTHFR polymorphism, the MTHFR 1298A > C one 
(rs1801131), causes Glu429Ala aminoacidic change. Meta-analysis revealed that the 
frequency of the MTHFR minor 1298C allele is higher in Asians (~40.0%), with 
little less frequency among Caucasians (~35.0%) and Brazilians (upto 25.0%) [22]. 
Interestingly, no studies have demonstrated MTHFR 1298A > C polymorphism is an 
independent maternal risk factor for the birth of a child with DS. Instead, However, 
case-control studies demonstrated that genotypes that carry both the MTHFR 
677C > T and 1298A > C polymorphisms increase the maternal risk synergistically 
for a birth of a child with trisomy 21 more than the presence of the single polymor-
phic site MTHFR 677C > T one alone. These observations suggest intuitive func-
tional interaction of both polymorphisms on protein stability and activity [25–29]. 
The maternal double homozygous 677TT-1298CC genotype leads to MTHFR 
protein instability and inactivity, often resulting in prenatal death [16].
6.  Methionine synthase and methionine synthase reductase (MTR and 
MTRR)
The gene named as 5-methyltetrahydrofolate-homocysteine methyltransferase 
(MTR) or methionine synthase in short is located at 1q43 and carries 33 exons. It is 
a cobalamin-dependent enzyme that catalyzes the transmethylation of homocystein 
to methionine and MTRR, which is a NADPH-dependent diflavin enzyme, needed 
for activation of MTR. On the other hand the gene5-methyltetrahydrofolate-
homocysteine methyltransferase reductase of MTRR is located at 5p15.31 in human 
genome. This protein functions in the synthesis of methionine by regenerating 
methionine synthase (MTR) to a functional state.
The second polymorphism of the gene MTRR that exhibited association with DS 
birth among North American women is rs1801394; 66A > G substitution which causes 
Ile22Met amino acid change [30]. Subsequent studies on different population samples 
provide conflicting results. Nevertheless, the meta-analysis conducted in 2009 on 
623 DS bearing and 936 control mothers [31], confirmed association of this polymor-
phism in maternal genome with the elevated risk of having DS baby. Further analyses 
with stratified data, performed in recent time [32, 33], suggest a significant effect in 
Caucasians under both dominant and recessive genetic models. The estimated score 
for minor Allele “G” among Caucasian women was 35.8–54.3%, among Brazilian 
women was from 40.0 to 48.0% and among Asian mothers was from 41.5 to 62.5% 
[32–34]. Furthermore, when Caucasian samples were stratified by geographic and 
demographic criteria the estimates revealed that the risk is higher in those of non-
residential European descent (OR = 1.47; 95% CI = 1.02–2.11; dominant model) than 
in residential European Caucasians (OR = 1.31; 95% CI = 1.01–1.70; dominant model). 
On contrary, when the study was conducted on the Caucasian from Mediterranean 
regions no significant association was observed (OR = 1.19; 95% CI = 0.91–1.55; domi-
nant model), which suggests that the manifestation of the effect of MTRR rs1801394 
66A > G is also dependent on geographic and dietary factors [33].
Recently, another MTRR polymorphism, namely MTRR 524C > T (rs1532268) 
that causes Ser175Leu replacement in peptide chain, has been identified as related to 
the maternal risk of birth of a child with DS [35] among Chinese women. This study 
reported decreased maternal risk for carriers of the 524 T allele that was associated 
with reduced hcy levels in Chinese women. But the study did not address the issue 
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of but did not analyze the linkage or interaction of MTRR 524C > T (rs1532268) 
with the MTRR 66A > G sites [35].
As far as published literatures on the MTR gene polymorphisms are concerned, 
the MTR 2756A > G polymorphism (rs1805087) in maternal genome, leading to the 
Asp919Gly substitution, was the third variant of the folate pathway to be associated 
with DS birth [36]. However, subsequent case-control studies failed to confirm this 
association, and recent meta-analyses confirmed that the MTR 2756A > G polymor-
phism is not an independent maternal risk factor for DS birth [20, 32, 37],  
rather a strong relation with MTRR 66A > G has been evident. The estimated 
frequency of minor allele ‘G’ of this polymorphic site in the European and mixed 
Brazilian populations of women having DS child is 18–21% [37], while the estimate 
is less than 10% in the Asian women [38]. A large cohort study on Italian popula-
tion samples [33, 37], revealed the MTRR 66A > G polymorphism, but not the MTR 
2756A > G one, was associated with increased serum folate levels among the GG 
carriers women. On the other hand study on Brazilian population has [29] reported 
association of MTRR AG and GG genotypes with high methylmalonic acid (MMA) 
concentrations, an indicator of the vitamin B12 status. However, when both the 
polymorphisms MTR 2756AA/MTRR 66GG were present in women having DS child 
exhibited association with increased serum folate levels, while the carriers of the 
MTR 2756GG/MTRR 66AA genotype exhibited reduced folate and hcy levels [33]. 
Such combined presence of MTHFR/MTRR or MTRR/MTR genotypes among the 
mother of DS, has been many reported by many authors who worked on different 
ethnic population samples [23, 33, 34, 36, 38, 39].
7. Reduced folate carrier (RFC1 or SLC19A1)
The gene is actually named solute carrier family 19 member 1, located at 21q22.3 
and carries 17 exons. The protein expresses ubiquitously and is the major trans-
port system in mammalian tissues for folate cofactors and regulates intracellular 
concentration of folate [40]. Though not universal, some workers have reported 
risk association with polymorphic allele in maternal genome with DS birth. The 
polymorphic variation RFC1 80G > A polymorphism (rs1051266), causes Arg27His 
replacement in protein chain. This polymorphic sites exhibited association with 
increased plasma hcy levels in homozygous GG genotype when present together 
with MTHFR 677TT [41] homozygous variants. Similarly study on Italian popula-
tion [42] observed a borderline significant association of maternal genotype RFC1 
80GG/MTHFR 677TT and DS birth and protective negative association with RFC1 
80(AA or AG)/MTHFR 1298AA genotypes. Two recent meta-analyses [20, 33]  
suggest that the polymorphism RFC1 80G > A is independent maternal risk fac-
tor for DS birth with ORs ranging from 1.1 to 1.3. When stratified analyses has 
been conducted, theRFC1 80G allele exhibited higher frequency in Caucasian and 
Brazilian women having DS child (ranging between 49.0 and 54.0%) than in Asian 
ones (36.0–36.5%) [33]. Further population based studies are needed to confirm the 
implication of this polymorphism as a maternal risk factor for DS birth.
8. Cystathionine β-synthase (CBS)
The gene is located on chromsome21 at 21q22.3 and encodes a hemoprotein 
that catalyzes the condensation of hcy and serine to form cystathionine in the 
transsulfuration pathway. This enzyme is activated by adenosyl methionine and 
pyridoxal phosphate acts as co-factor in this reaction. So far published literatures 
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are concerned two common polymorphisms have been studied as maternal risk 
factors for DS birth. One of them is an insertion of 68-bp within exon 8 that results 
in the duplication of a splice site at the intron7/exon 8 junction of the gene [43]. 
Very recent meta-analyses, performed with 825 mothers of DS child and 1.034 
control did not find association of the CBS 844ins68 allele and maternal risk of 
having a DS child [20, 32]. The second polymorphic variants is an 833 T > C sub-
stitution (rs5742905) that causes missense mutationIle278Thr associated with mild 
hyperhomocysteinemia [44]. Results of association studies related to this site are 
contradictory and non-conclusive [29, 35], so further study is warrant to reveal its 
implication in DS birth.
9. Methylenetetrahydrofolate dehydrogenase (MTHFD1)
The genetic position of this gene is 14q23.3 and three distinct enzymatic activi-
ties, 5,10-methylenetetrahydrofolate-dehydrogenase,-5,10-methenyltetrahydro-
folate-cyclohydrolase and 10-formyltetrahydrofolate synthetase. Each of these 
activities catalyzes one of the three sequential reactions in the interconversion 
of 1-carbon derivatives of tetrahydrofolate. The MTHFD1 1958G > A polymor-
phism (rs2236225), that causes missense change Arg653Gln which in turn reduces 
enzyme stability and activity and was first identified maternal genetic risk factor 
for trisomy 21 in Southern Italian women, exhibited association with DS risk in 
combination-with-the RFC1 80G > A-polymorphism-(the combined MTHFD1 
1958AA/RFC180GG genotype) [27]. The results of subsequent studies on other 
population were contradictory [29, 38, 45, 46]. Very recent meta-analysis [32] that 
included 497 mothers of Ds child and 930 controls, revealed a weak association with 
maternal heterozygous GA genotype than GG homozygous carriers (OR = 1.33; 
95% CI = 1.01–1.75). The result of this single study may not sufficient to draw any 
inference and more study on other populations is warrant.
10. Transcobalamin (TCN2)
The gene is located on chromosome 22 at 22q12.2. This protein can bind cobala-
min and helps in its cellular uptake by specific membrane receptors (TCR). The 
study of this gene for its association with DS birth is limited. A common variant 
TCN2 776C > G (rs1801198), that results in Arg232Pro replacement and impairs 
cobalamin metabolism [47] exhibited association with maternal risk of DS birth 
either alone [29], or in combination with MTR or MTHFR variants. The genotype 
TCN2 776CC/MTR 2756AG-[48]-or TCN2 776CG/MTHFR 677TT [38] have shown 
association with DS birth. But recent meta-analysis [32] did not confirm this asso-
ciation. The second polymorphism of that gene namely TCN2 67A > G (rs9606756) 
that causes Ile23Val substitution has been studied only in Brazilian population and 
did not find any association with maternal risk for a DS birth [29].
11. DNA methyltransferase 3B (DNMT3B)
This gene is located on chromosome 20 at 20q11.21 and encodes a de novo DNA 
methyl transferase. The enzyme is located primarily in nucleus and developmen-
tally regulated. Two recent independent studies one on Italian and another on 
Indian population suggested the polymorphisms of DNMT3B might be associated 
with DS birth as maternal risk factors. In the study on Italian population [37] the 
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authors genotyped 172 mothers with DS and 157 control mothers and found a 
decreased risk of birth of a child with DS among the mother who are carrier of 
DNMT3B 579G > T (rs1569686) minor allele T. Further, the author suggested that 
the combined DNMT3B-579GT/-149CC genotype was associated with an even more 
reduced maternal risk of birth of DS. That means the said genotypes have some 
protective implication on chromosome 21 NDJ. In Indian study [49] the author 
tested 150 mothers with Down syndrome and 172 control and found no significant 
difference in allelic and genotype frequency for individual loci between cases and 
controls, but found a significant difference in the frequency of haplotype rs1569686 
-579G: rs2424913 -149 T which exhibited preferential occurrence among the DS 
child bearing mothers. Further study is needed to validate this association.
12.  Serine-hydroxymethyltransferase (SHMT), thymidylate synthase 
(TYMS), and dihydrofolate reductase (DHFR)
The gene SHMTTYMS and DHFR are located at 17p11.2, 18p11.32 and 5q14.1 
respectively. SHMT coverts tetrahydrofolate (THF) into 5,10-methyleneTHF using 
serine as the one-carbon donor. This THF is then used for thymidylate synthesis in 
the reaction catalyzed by TYMS that produces dTMP and dihydrofolate (DHF). DHF 
is then reduced back to THF by DHFR. As far published literatures are concerned the 
polymorphisms of SHMT, TYMS, and DHFR have been analyzed as maternal risk 
factors for DS birth only in one case-control study each [50–52]. The SHMT1420C > T 
polymorphism (rs1979277), which causes Leu474Phe replacement and defects in 
nuclear transport of SHMT, was investigated [53] in 105 DS bearing and 185 control 
mothers from Brazil, and both the homozygous and 1420CT heterozygous genotypes 
exhibited decreased maternal risk of birth of a child with DS in comparison to the 
1420TT genotype [52]. A team of Italian researchers [50] investigated two common 
TYMS polymorphisms in 94 DS bearing and 113 control mothers from the popula-
tion of Italy. These polymorphisms were rs34743033, which is a 28-bp short tandem 
repeats in the 5′-untranslated region (5′-UTR) that is linked to gene expression levels 
[54], andrs34489327, which is a 6-bp deletion (1494 ins/del) polymorphism in the 
3′-UTR that causes mRNA instability into the cytoplasm [55, 56]. But the result sug-
gested no independent association of these two polymorphic sites with DS birth, but 
synergistic effect of the combined MTHFR 1298 AC/TYMS 28-bp 2R/2R genotype 
resulted in decreased maternal risk. Regarding DHFR gene polymorphism, only 
known study [51], was conducted including 105 DS bearing and 185 control mothers 
from Brazilian population for rs70991108 which is the presence of a 19-bp ins/del 
polymorphism, but no association with maternal risk of a DS birth was detected. But 
the confirmation of these results has not possible due to lack of replication of study in 
other populations.
13. Discussion and conclusion
Risk factors associated with Down syndrome birth the enigmatic. Both the 
genetic and environmental and habitual implications are known to be associated 
with DS birth. Regarding maternal genotypes that may impose risk of chromosome 
21 nondisjunction in oocyte is extremely complicated owing to multifactorial nature 
of chromosome segregation system. It includes genes that are involved directly in 
chromosome segregation and also, cell cycle regulators, replication and recombina-
tion regulators, and metabolism regulators that maintain the optimum nutrient 
level affecting the genetic and epigenetic environment. In respect to recombination 
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regulators, only gene that has been investigated in maternal genome is PRDM9. This 
study [9] is only known analyses on that gene and is needed to be replicated in other 
populations. Another gene is APOE that exhibited association with DS birth when 
APOE4 allele is present. Again very limited study has been conducted in this regard. 
Rest of the genes that have analyses so far in maternal genome for association with 
DS child are from folate metabolism regulators. Since the initial publication [17] on 
relation between DS birth risk and folate metabolism regulator polymorphisms in 
the year1999, several studies on different ethnic populations have been carried and 
the results are conflicting. But considering the gene X environment concept, it can 
be justified. The defects in folate metabolism pathways can only be manifested in 
term of chromosome segregation errors when genetic background interacts with 
nutritional status of the women. As the genetic background is different for different 
ethnic populations and as the nutritional level vary according to social architecture 
of given population, the association study gives different and contradictory results. 
Moreover, level of folic acid in grand maternal genome is of scientific concern as the 
oocytes starts growing in the fetal ovary.
In summary, it can be said that genetic architecture of maternal genome is 
needed to be explored in relation to prevention of DS child birth. Population spe-
cific genetic markers are needed to be developed in order to screen the women prior 
to their conception to test the genetic susceptibility for DS fetal conception. The 
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